首页 > 最新文献

Modern Pathology最新文献

英文 中文
MSAI-Path: Predicting Microsatellite Instability From Routine Histology Slides Without Reinventing the Wheel MSAI-Path:通过常规组织学切片预测微卫星不稳定性,无需重新发明轮子。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-07 DOI: 10.1016/j.modpat.2025.100932
Elias Baumann , Luca E.M. Schäfer , Frédérique Meeuwsen , Richard Kirsch , Iris D. Nagtegaal , Martin D. Berger , Heather Dawson , Inti Zlobec
Microsatellite instability (MSI) is an important biomarker in colorectal cancer, influencing both patient prognosis and treatment decisions. Current approaches for MSI prediction from hematoxylin and eosin--stained whole-slide images (WSI) rely on end-to-end deep learning (“black-box”) models with limited interpretability, often relying on heatmaps for visualization. However, experienced pathologists can intuitively identify MSI through specific histologic features and have developed manual classification systems such as MS-Path for Lynch syndrome screening. We present a novel hybrid approach that combines computational and pathologist expertise to create an explainable and verifiable method for MSI prediction in colorectal cancer, applicable to resection and biopsy WSI. Our proposed method uses nuclei and tissue segmentation models to automatically quantify MSI-associated histologic features outlined in the Bethesda guidelines, including intraepithelial lymphocytes, grade of differentiation, mucinous components, and tertiary lymphoid structures. After validation on annotated data sets, these features are integrated with clinical data and used in logistic regression and random forest models to predict MSI status. We validated our approach using 3256 WSI from 2267 patients across 7 cohorts from 5 centers. The method achieved an area under the curve of up to 0.88 across all resection cohorts, and 0.90 on biopsies, performing on par with published black-box deep learning models. Importantly, the learned variable importances strongly correlated with manual scoring systems and aligned with manual pathologist assessments. We observed significant intrapatient heterogeneity in predicted scores, emphasizing the importance of whole-case analysis. Our approach also shows potential as a screening tool that could exclude 41% of patients from gold-standard MSI testing while maintaining 95% sensitivity. This study demonstrates that classifiers based on clinical and validated histologic information can predict MSI status as effectively as black-box models while providing complete interpretability. Our method offers an alternative pathway for understandable, explainable, and trustworthy biomarker prediction in computational pathology.
微卫星不稳定性(Microsatellite instability, MSI)是结直肠癌的重要生物标志物,影响患者预后和治疗决策。目前,从苏木精和伊红染色的整张幻灯片图像(WSI)中预测MSI的方法依赖于端到端深度学习(“黑盒”)模型,可解释性有限,通常依赖热图进行可视化。同时,经验丰富的病理学家可以通过特定的组织学特征直观地识别MSI,并开发了MS-Path等人工分类系统用于Lynch综合征筛查。我们提出了一种新的混合方法,结合了计算和病理学家的专业知识,创造了一种可解释和可验证的方法来预测结直肠癌的MSI,适用于切除和活检的WSI。我们提出的方法使用核和组织分割模型来自动量化Bethesda指南中概述的msi相关组织学特征,包括上皮内淋巴细胞、分化等级、粘液成分和三级淋巴组织结构。在对注释数据集进行验证后,这些特征与临床数据相结合,并用于逻辑回归和随机森林模型来预测MSI状态。我们使用来自5个中心的7个队列的2267名患者的3256例WSI来验证我们的方法。该方法在所有切除队列中实现了高达0.88的曲线下面积,在活检中实现了0.90,与已发表的黑箱深度学习模型相当。重要的是,学习变量的重要性与人工评分系统密切相关,并与人工病理学家的评估一致。我们观察到预测评分存在显著的患者内部异质性,强调了全病例分析的重要性。我们的方法也显示出作为筛查工具的潜力,可以将41%的患者排除在金标准MSI检测之外,同时保持95%的灵敏度。这项工作表明,基于临床和经过验证的组织学信息的分类器可以像黑盒模型一样有效地预测MSI状态,同时提供完全的可解释性。我们的方法为计算病理学中可理解、可解释和可信赖的生物标志物预测提供了另一种途径。
{"title":"MSAI-Path: Predicting Microsatellite Instability From Routine Histology Slides Without Reinventing the Wheel","authors":"Elias Baumann ,&nbsp;Luca E.M. Schäfer ,&nbsp;Frédérique Meeuwsen ,&nbsp;Richard Kirsch ,&nbsp;Iris D. Nagtegaal ,&nbsp;Martin D. Berger ,&nbsp;Heather Dawson ,&nbsp;Inti Zlobec","doi":"10.1016/j.modpat.2025.100932","DOIUrl":"10.1016/j.modpat.2025.100932","url":null,"abstract":"<div><div>Microsatellite instability (MSI) is an important biomarker in colorectal cancer, influencing both patient prognosis and treatment decisions. Current approaches for MSI prediction from hematoxylin and eosin--stained whole-slide images (WSI) rely on end-to-end deep learning (“black-box”) models with limited interpretability, often relying on heatmaps for visualization. However, experienced pathologists can intuitively identify MSI through specific histologic features and have developed manual classification systems such as MS-Path for Lynch syndrome screening. We present a novel hybrid approach that combines computational and pathologist expertise to create an explainable and verifiable method for MSI prediction in colorectal cancer, applicable to resection and biopsy WSI. Our proposed method uses nuclei and tissue segmentation models to automatically quantify MSI-associated histologic features outlined in the Bethesda guidelines, including intraepithelial lymphocytes, grade of differentiation, mucinous components, and tertiary lymphoid structures. After validation on annotated data sets, these features are integrated with clinical data and used in logistic regression and random forest models to predict MSI status. We validated our approach using 3256 WSI from 2267 patients across 7 cohorts from 5 centers. The method achieved an area under the curve of up to 0.88 across all resection cohorts, and 0.90 on biopsies, performing on par with published black-box deep learning models. Importantly, the learned variable importances strongly correlated with manual scoring systems and aligned with manual pathologist assessments. We observed significant intrapatient heterogeneity in predicted scores, emphasizing the importance of whole-case analysis. Our approach also shows potential as a screening tool that could exclude 41% of patients from gold-standard MSI testing while maintaining 95% sensitivity. This study demonstrates that classifiers based on clinical and validated histologic information can predict MSI status as effectively as black-box models while providing complete interpretability. Our method offers an alternative pathway for understandable, explainable, and trustworthy biomarker prediction in computational pathology.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100932"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BRAF p.Val600Glu Mutations Are Not Detected in Adenomatoid Odontogenic Tumors BRAF p.Val600Glu突变未在腺瘤样牙源性肿瘤中检测到。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-07 DOI: 10.1016/j.modpat.2025.100933
Josiane Gonçalves , Bruna P. Coura , Vanessa F. Bernardes , Luiz A. De Marco , Manoela D. Martins , Danyel E. da C. Perez , Ricardo S. Gomez , Carolina C. Gomes
The adenomatoid odontogenic tumor (AOT) is a benign, encapsulated odontogenic tumor characterized by slow growth and indolent behavior. AOT shows mitogen-activated protein kinase/ERK pathway activation, and KRAS p.Gly12Val or p.Gly12Arg mutations occur in 70% of cases. The molecular events underlying the pathogenesis of the other 30% of cases remain unclear. The BRAF p.Val600Glu mutation was reported by a single study in 2 AOT cases, 1 of which also harbored KRAS p.Gly12Val. Given that BRAF p.Val600Glu has not been previously detected in AOT and that BRAF and KRAS mutations are mutually exclusive, we aimed to assess BRAF p.Val600Glu irrespective of KRAS mutational status to explore the potential involvement of BRAF mutations in AOT pathogenesis and the co-occurrence of BRAF and KRAS mutations. Whereas KRAS codon 13 and 61 hotspot mutations have not been previously detected in AOT, KRAS codon 146 hotspot mutations have been investigated in a few AOT cases to date. Therefore, we further sequenced KRAS codon 146 in KRAS codon 12 wild-type cases. A total of 29 AOT samples, including 21 KRAS codon 12 mutation-positive cases and 8 wild-type cases, were evaluated for the BRAF p.Val600Glu pathogenic mutation using allele-specific qPCR and/or Sanger sequencing. In addition, KRAS codon 146 was Sanger sequenced in 4 out of 29 samples. BRAF p.Val600Glu was not detected in any of the 29 AOT cases evaluated, either alone or as a comutation with KRAS mutations. All codon 12 wild-type cases were wild-type for KRAS codon 146 mutations. These findings reinforce that KRAS codon 12 mutant alleles predominate in the context of AOT tumorigenesis, whereas BRAF p.Val600Glu does not constitute a molecular feature of this tumor and the presence of the BRAF mutation does not support the diagnosis of AOT in challenging cases. In addition, the results further strengthen the notion that BRAF and KRAS mutations are mutually exclusive events.
腺瘤样牙源性肿瘤(AOT)是一种良性的、被包裹的牙源性肿瘤,其特征是生长缓慢和惰性行为。AOT显示MAPK/ERK通路激活,70%的病例发生KRAS p.Gly12Val或p.Gly12Arg突变。其他30%病例发病机制背后的分子事件尚不清楚。一项研究在2例AOT病例中报道了BRAF p.Val600Glu突变,其中1例也携带KRAS p.Gly12Val。鉴于此前未在AOT中检测到BRAF p.Val600Glu,且BRAF和KRAS突变是互排斥的,我们的目的是在不考虑KRAS突变状态的情况下评估BRAF p.Val600Glu,以探讨BRAF突变在AOT发病中的潜在参与以及BRAF和KRAS突变的共现性。KRAS密码子13和61热点突变在AOT中未被发现,KRAS密码子146热点突变仅在少数AOT病例中被发现。因此,我们进一步对KRAS密码子12野生型病例中的KRAS密码子146进行了测序。采用等位基因特异性qPCR和/或Sanger测序对29份AOT样本进行BRAF p.Val600Glu致病性突变检测,包括21例KRAS密码子12突变阳性病例和8例野生型病例。此外,在4/29份样本中对KRAS密码子146进行了Sanger测序。在评估的29例AOT病例中,无论是单独还是与KRAS突变共突变,均未检测到BRAF p.Val600Glu。所有密码子12野生型病例均为KRAS密码子146突变的野生型。这些发现强化了KRAS密码子12突变等位基因在AOT肿瘤发生中占主导地位,而BRAF p.Val600Glu不构成该肿瘤的分子特征,并且BRAF突变的存在不支持在挑战性病例中诊断AOT。此外,结果进一步强化了BRAF和KRAS突变是互斥事件的观点。
{"title":"BRAF p.Val600Glu Mutations Are Not Detected in Adenomatoid Odontogenic Tumors","authors":"Josiane Gonçalves ,&nbsp;Bruna P. Coura ,&nbsp;Vanessa F. Bernardes ,&nbsp;Luiz A. De Marco ,&nbsp;Manoela D. Martins ,&nbsp;Danyel E. da C. Perez ,&nbsp;Ricardo S. Gomez ,&nbsp;Carolina C. Gomes","doi":"10.1016/j.modpat.2025.100933","DOIUrl":"10.1016/j.modpat.2025.100933","url":null,"abstract":"<div><div>The adenomatoid odontogenic tumor (AOT) is a benign, encapsulated odontogenic tumor characterized by slow growth and indolent behavior. AOT shows mitogen-activated protein kinase/ERK pathway activation, and <em>KRAS</em> p.Gly12Val or p.Gly12Arg mutations occur in 70% of cases. The molecular events underlying the pathogenesis of the other 30% of cases remain unclear. The <em>BRAF</em> p.Val600Glu mutation was reported by a single study in 2 AOT cases, 1 of which also harbored <em>KRAS</em> p.Gly12Val. Given that <em>BRAF</em> p.Val600Glu has not been previously detected in AOT and that <em>BRAF</em> and <em>KRAS</em> mutations are mutually exclusive, we aimed to assess <em>BRAF</em> p.Val600Glu irrespective of <em>KRAS</em> mutational status to explore the potential involvement of <em>BRAF</em> mutations in AOT pathogenesis and the co-occurrence of <em>BRAF</em> and <em>KRAS</em> mutations. Whereas <em>KRAS</em> codon 13 and 61 hotspot mutations have not been previously detected in AOT, <em>KRAS</em> codon 146 hotspot mutations have been investigated in a few AOT cases to date. Therefore, we further sequenced <em>KRAS</em> codon 146 in <em>KRAS</em> codon 12 wild-type cases. A total of 29 AOT samples, including 21 <em>KRAS</em> codon 12 mutation-positive cases and 8 wild-type cases, were evaluated for the <em>BRAF</em> p.Val600Glu pathogenic mutation using allele-specific qPCR and/or Sanger sequencing. In addition, <em>KRAS</em> codon 146 was Sanger sequenced in 4 out of 29 samples. <em>BRAF</em> p.Val600Glu was not detected in any of the 29 AOT cases evaluated, either alone or as a comutation with <em>KRAS</em> mutations. All codon 12 wild-type cases were wild-type for <em>KRAS</em> codon 146 mutations. These findings reinforce that <em>KRAS</em> codon 12 mutant alleles predominate in the context of AOT tumorigenesis, whereas <em>BRAF</em> p.Val600Glu does not constitute a molecular feature of this tumor and the presence of the <em>BRAF</em> mutation does not support the diagnosis of AOT in challenging cases. In addition, the results further strengthen the notion that <em>BRAF</em> and <em>KRAS</em> mutations are mutually exclusive events.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100933"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA Methylation Profiling Classifies and Reveals Origin of Gynecologic Central Nervous System-Like Tumors DNA甲基化分析分类和揭示妇科中枢神经系统样肿瘤的起源。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-22 DOI: 10.1016/j.modpat.2025.100941
Lucy Wang , Varshini Vasudevaraja , Jonathan Serrano , Jennifer Kerkhof , Jessica Rzasa , Stephen Kelly , Esther Oliva , Robert H. Young , Lars-Christian Horn , Kay J. Park , Amir Momeni-Boroujeni , Cristina R. Antonescu , Nadeem R. Abu-Rustum , Yanming Zhang , Lu Wang , Achim Jungbluth , Marc K. Rosenblum , Bekim Sadikovic , Igor Dolgalev , Matija Snuderl , Sarah Chiang
Gynecologic neuroectodermal tumors either exhibit central nervous system (CNS) differentiation (CNS-like) or represent Ewing sarcoma (EWS), which lacks CNS features and harbors FET-ETS gene fusions. DNA methylation profiling reclassified CNS primitive neuroectodermal tumors into common CNS neoplasms or embryonal tumors with specific epigenetic/genetic characteristics. Its utility in classifying gynecologic neuroectodermal tumors is unknown. Whole-genome DNA methylation profiling was performed on 26 gynecologic neuroectodermal tumors (22 CNS-like tumors, 4 EWS) arising in the ovary, paratubal soft tissue, uterus, and vulva, which were classified by using sarcoma and CNS tumor DNA methylation classifiers. Sarcoma-related gene fusions were confirmed by fluorescence in situ hybridization or targeted RNA next-generation sequencing. Tumor-only whole-exome sequencing (WES) was performed in 13 cases. Copy number alterations and zygosity were inferred from DNA methylation array and WES data. Methylation abnormalities associated with imprinting were examined. The sarcoma methylation classifier identified EWS (n = 3) and high-grade endometrial stromal sarcoma (n = 1), confirmed by fluorescence in situ hybridization or next-generation sequencing detection of EWSR1 and YWHAE rearrangements, respectively. The remaining CNS-like tumors were classified by DNA methylation with positive/valid (n = 4), indeterminate (n = 9), and negative (n = 9) scores at the family level. Methylation subclasses included teratoma; embryonal tumor with multilayered rosettes, atypical; medulloblastoma, SHH-activated, subtype 3; medulloblastoma, group 3; intraocular medulloepithelioma; supratentorial ependymoma, ZFTA::RELA fused, subclass A; and diffuse pediatric-type high-grade glioma, MYCN subtype. Male biological sex was predicted in 54% of methylation-confirmed CNS-like tumors and none of the sarcomas. Among CNS-like tumors, copy number analyses identified genome-wide chromosomal gains and losses, and WES revealed genome-wide allelic imbalance suggestive of genome-wide duplications. Epigenetic imprinting analyses showed increased paternal or maternal imprinting signal across multiple chromosomes, suggesting uniparental duplication. DNA methylation profiling successfully classified gynecologic neuroectodermal tumors as known CNS tumors or sarcoma entities. Epigenetic and exomic studies indicate a male genome and increased maternal allelic contribution in CNS-like tumors, suggesting development via conception or chimerism.
妇科神经外胚层肿瘤要么表现为中枢神经系统(CNS)分化(CNS样),要么表现为Ewing肉瘤(EWS),后者缺乏中枢神经系统特征,携带FET-ETS基因融合。DNA甲基化分析将中枢神经系统原始神经外胚层肿瘤重新分类为普通中枢神经系统肿瘤或具有特定表观遗传/遗传特征的胚胎性肿瘤。它在妇科神经外胚层肿瘤分类中的应用尚不清楚。对26例发生于卵巢、输卵管旁软组织、子宫和外阴的妇科神经外胚层肿瘤(CNS样肿瘤22例,EWS 4例)进行全基因组DNA甲基化分析,并采用肉瘤和CNS肿瘤DNA甲基化分类器进行分类。通过荧光原位杂交(FISH)或靶向RNA下一代测序(NGS)证实了肉瘤相关基因融合。13例进行肿瘤全外显子组测序(WES)。从DNA甲基化阵列和WES数据推断拷贝数改变和合子性。研究了与印迹相关的甲基化异常。肉瘤甲基化分类器分别通过FISH或NGS检测EWSR1和YWHAE重排确诊为EWS (n=3)和高级别子宫内膜间质肉瘤(n=1)。其余的cns样肿瘤通过DNA甲基化分类,在家族水平上分为阳性/有效(n=4)、不确定(n=9)和阴性(n=9)。甲基化亚类包括畸胎瘤;具有多层莲座的胚胎性肿瘤,不典型;髓母细胞瘤,shh激活,亚型3;髓母细胞瘤,第3组;眼内medulloepithelioma;幕上室管膜瘤,ZFTA::RELA融合,A亚类;弥漫性小儿型高级别胶质瘤,MYCN亚型。男性在54%的甲基化证实的cns样肿瘤中被预测,而在肉瘤中没有被预测。在cns样肿瘤中,拷贝数分析确定了全基因组的染色体增益和损失,WES揭示了全基因组的等位基因失衡,提示全基因组的重复。表观遗传印迹分析显示,父本或母本印迹信号在多个染色体上增加,表明单代复制。DNA甲基化分析成功地将妇科神经外胚层肿瘤分类为已知的中枢神经系统肿瘤或肉瘤实体。表观遗传学和外显组学研究表明,在中枢神经系统样肿瘤中,男性基因组和母体等位基因的贡献增加,表明通过受孕或嵌合发展。
{"title":"DNA Methylation Profiling Classifies and Reveals Origin of Gynecologic Central Nervous System-Like Tumors","authors":"Lucy Wang ,&nbsp;Varshini Vasudevaraja ,&nbsp;Jonathan Serrano ,&nbsp;Jennifer Kerkhof ,&nbsp;Jessica Rzasa ,&nbsp;Stephen Kelly ,&nbsp;Esther Oliva ,&nbsp;Robert H. Young ,&nbsp;Lars-Christian Horn ,&nbsp;Kay J. Park ,&nbsp;Amir Momeni-Boroujeni ,&nbsp;Cristina R. Antonescu ,&nbsp;Nadeem R. Abu-Rustum ,&nbsp;Yanming Zhang ,&nbsp;Lu Wang ,&nbsp;Achim Jungbluth ,&nbsp;Marc K. Rosenblum ,&nbsp;Bekim Sadikovic ,&nbsp;Igor Dolgalev ,&nbsp;Matija Snuderl ,&nbsp;Sarah Chiang","doi":"10.1016/j.modpat.2025.100941","DOIUrl":"10.1016/j.modpat.2025.100941","url":null,"abstract":"<div><div>Gynecologic neuroectodermal tumors either exhibit central nervous system (CNS) differentiation (CNS-like) or represent Ewing sarcoma (EWS), which lacks CNS features and harbors FET-ETS gene fusions. DNA methylation profiling reclassified CNS primitive neuroectodermal tumors into common CNS neoplasms or embryonal tumors with specific epigenetic/genetic characteristics. Its utility in classifying gynecologic neuroectodermal tumors is unknown. Whole-genome DNA methylation profiling was performed on 26 gynecologic neuroectodermal tumors (22 CNS-like tumors, 4 EWS) arising in the ovary, paratubal soft tissue, uterus, and vulva, which were classified by using sarcoma and CNS tumor DNA methylation classifiers. Sarcoma-related gene fusions were confirmed by fluorescence in situ hybridization or targeted RNA next-generation sequencing. Tumor-only whole-exome sequencing (WES) was performed in 13 cases. Copy number alterations and zygosity were inferred from DNA methylation array and WES data. Methylation abnormalities associated with imprinting were examined. The sarcoma methylation classifier identified EWS (n = 3) and high-grade endometrial stromal sarcoma (n = 1), confirmed by fluorescence in situ hybridization or next-generation sequencing detection of <em>EWSR1</em> and <em>YWHAE</em> rearrangements, respectively. The remaining CNS-like tumors were classified by DNA methylation with positive/valid (n = 4), indeterminate (n = 9), and negative (n = 9) scores at the family level. Methylation subclasses included teratoma; embryonal tumor with multilayered rosettes, atypical; medulloblastoma, SHH-activated, subtype 3; medulloblastoma, group 3; intraocular medulloepithelioma; supratentorial ependymoma, <em>ZFTA::RELA</em> fused, subclass A; and diffuse pediatric-type high-grade glioma, MYCN subtype. Male biological sex was predicted in 54% of methylation-confirmed CNS-like tumors and none of the sarcomas. Among CNS-like tumors, copy number analyses identified genome-wide chromosomal gains and losses, and WES revealed genome-wide allelic imbalance suggestive of genome-wide duplications. Epigenetic imprinting analyses showed increased paternal or maternal imprinting signal across multiple chromosomes, suggesting uniparental duplication. DNA methylation profiling successfully classified gynecologic neuroectodermal tumors as known CNS tumors or sarcoma entities. Epigenetic and exomic studies indicate a male genome and increased maternal allelic contribution in CNS-like tumors, suggesting development via conception or chimerism.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100941"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Carcinoma Metastatic to the Breast: A Comprehensive Analysis of Clinical Presentation, Morphologic, and Molecular Features, With Emphasis on Diagnostic Pitfalls 肺癌转移到乳房:临床表现、形态学和分子特征的综合分析,重点是诊断缺陷。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-13 DOI: 10.1016/j.modpat.2025.100936
Atif Ali Hashmi, Theodore Vougiouklakis, Andrea Gazzo, Hannah Y. Wen, Dara Ross, Fresia Pareja, Edi Brogi
Lung carcinoma metastatic to the breast (bLM) or axillary lymph nodes (lnLM) may closely mimic primary triple-negative breast carcinoma (BC), leading to possible misdiagnosis. We characterized the clinical, morphologic, and molecular features of a series of lung carcinomas metastatic to breast and regional lymph nodes to identify diagnostic clues and pitfalls. The study cohort consisted of 30 patients (27 women, 3 men) with a median age of 72 years (range, 46-86); 21 patients (70%) reported a smoking history. At the time of the index biopsy, 4 patients (13.3%) had no history of lung carcinoma. Most tumors (n = 25, 83.3%) were bLM; 4 (13.3%) were lnLM, and 1 was a supraclavicular lymph node metastasis. In 7 of 23 cases (30.4%) with available paired imaging studies, the bLM was larger than the lung tumor. Of the 30 cases, 26 (86.7%) were adenocarcinomas, 2 (6.7%) were small cell carcinomas, and 2 (6.7%) were atypical carcinoids. Metastatic adenocarcinoma resembled BC with apocrine morphology in 16 of 30 cases (53.3%), 6 cases (20%) had vacuolated cytoplasm, and 6 (20%) had micropapillary features. One bLM closely mimicked ductal carcinoma in situ morphologically, and another case showed peripheral expression of CK5/14 and p63 mimicking myoepithelium around ductal carcinoma in situ. Initial diagnosis of BC had been rendered in 7 cases (6 adenocarcinomas and 1 small cell carcinoma). Molecular analysis of 18 cases showed that the most altered cancer genes were TP53 (44%), KRAS (44%), CDKN2A (33%), and MTAP (31%). Compared with a cohort of primary triple-negative BC, the bLM/lnLM exhibited a higher tumor mutation burden (P = .002), a lower rate of TP53 mutations, and more frequently harbored genetic alterations in KRAS, RBM10, CDKN2A, CDKN2B, SMARCA4, and STK11. In 10 of 18 cases, mutational signature analysis revealed a dominant smoking signature, providing evidence of lung origin. Our findings unveil diagnostic pitfalls that may warrant additional evaluation to avoid misdiagnosis of metastatic lung carcinoma as a primary BC.
肺癌转移到乳房(bLM)或腋窝淋巴结(LnLM)可能非常类似原发性三阴性乳腺癌(BC),导致可能的误诊。我们描述了一系列转移到乳房和区域淋巴结的肺癌的临床,形态学和分子特征,以确定诊断线索和陷阱。研究队列包括30例患者(27例女性,3例男性),中位年龄72岁(46-86岁);21例(70%)患者报告有吸烟史。指数活检时,4例(13.3%)患者无肺癌病史。多数肿瘤为bLM(25例,83.3%);4例(13.3%)为LnLM, 1例为锁骨上淋巴结转移。在23例有配对影像学检查的病例中,有7例(30.4%)bLM大于肺肿瘤。30例中腺癌26例(86.7%),小细胞癌2例(6.7%),非典型类癌2例(6.7%)。转移性腺癌16/30(53.3%)表现为大汗腺形态与BC相似,6例(20%)表现为细胞质空泡化,6例(20%)表现为微乳头状。1例bLM在形态学上与导管原位癌(ductal carcinoma in situ, DCIS)非常相似,另1例在DCIS周围表达CK5/14和p63模拟肌上皮。7例初步诊断为BC(6例腺癌,1例小细胞癌)。18例患者的分子分析显示,改变最多的癌基因是TP53(44%)、KRAS(44%)、CDKN2A(33%)和MTAP(31%)。与原发性三阴性BC相比,bLM/LnLM表现出更高的TMB (p=0.002),更低的TP53突变率,更频繁地携带KRAS, RBM10, CDKN2A, CDKN2B, SMARCA4和STK11的遗传改变。在10/18例中,突变特征分析显示吸烟特征占主导地位,为肺部起源提供了证据。我们的发现揭示了诊断缺陷,可能需要额外的评估,以避免误诊转移性肺癌为原发性乳腺癌。
{"title":"Lung Carcinoma Metastatic to the Breast: A Comprehensive Analysis of Clinical Presentation, Morphologic, and Molecular Features, With Emphasis on Diagnostic Pitfalls","authors":"Atif Ali Hashmi,&nbsp;Theodore Vougiouklakis,&nbsp;Andrea Gazzo,&nbsp;Hannah Y. Wen,&nbsp;Dara Ross,&nbsp;Fresia Pareja,&nbsp;Edi Brogi","doi":"10.1016/j.modpat.2025.100936","DOIUrl":"10.1016/j.modpat.2025.100936","url":null,"abstract":"<div><div>Lung carcinoma metastatic to the breast (bLM) or axillary lymph nodes (lnLM) may closely mimic primary triple-negative breast carcinoma (BC), leading to possible misdiagnosis. We characterized the clinical, morphologic, and molecular features of a series of lung carcinomas metastatic to breast and regional lymph nodes to identify diagnostic clues and pitfalls. The study cohort consisted of 30 patients (27 women, 3 men) with a median age of 72 years (range, 46-86); 21 patients (70%) reported a smoking history. At the time of the index biopsy, 4 patients (13.3%) had no history of lung carcinoma. Most tumors (n = 25, 83.3%) were bLM; 4 (13.3%) were lnLM, and 1 was a supraclavicular lymph node metastasis. In 7 of 23 cases (30.4%) with available paired imaging studies, the bLM was larger than the lung tumor. Of the 30 cases, 26 (86.7%) were adenocarcinomas, 2 (6.7%) were small cell carcinomas, and 2 (6.7%) were atypical carcinoids. Metastatic adenocarcinoma resembled BC with apocrine morphology in 16 of 30 cases (53.3%), 6 cases (20%) had vacuolated cytoplasm, and 6 (20%) had micropapillary features. One bLM closely mimicked ductal carcinoma in situ morphologically, and another case showed peripheral expression of CK5/14 and p63 mimicking myoepithelium around ductal carcinoma in situ. Initial diagnosis of BC had been rendered in 7 cases (6 adenocarcinomas and 1 small cell carcinoma). Molecular analysis of 18 cases showed that the most altered cancer genes were <em>TP53</em> (44%), <em>KRAS</em> (44%), <em>CDKN2A</em> (33%), and <em>MTAP</em> (31%). Compared with a cohort of primary triple-negative BC, the bLM/lnLM exhibited a higher tumor mutation burden (<em>P</em> = .002), a lower rate of <em>TP53</em> mutations, and more frequently harbored genetic alterations in <em>KRAS</em>, <em>RBM10</em>, <em>CDKN2A</em>, <em>CDKN2B</em>, <em>SMARCA4</em>, and <em>STK11</em>. In 10 of 18 cases, mutational signature analysis revealed a dominant smoking signature, providing evidence of lung origin. Our findings unveil diagnostic pitfalls that may warrant additional evaluation to avoid misdiagnosis of metastatic lung carcinoma as a primary BC.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100936"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining the Spectrum of Epstein-Barr Virus–Positive (EBV+) Diffuse Large B-cell Lymphoma and EBV+ Classic Hodgkin Lymphoma 重新定义ebv阳性弥漫性大b细胞淋巴瘤和ebv阳性经典霍奇金淋巴瘤的谱。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-08 DOI: 10.1016/j.modpat.2025.100950
Shunsuke Nagase , Naoya Nakamura , Yara Yukie Kikuti , Joaquim Carreras , Yuki Tanigaki , Makoto Orita , Atsushi Ito , Haruka Ikoma , Hiroshi Kawada , Yohei Masugi
Epstein-Barr virus–positive (EBV+) diffuse large B-cell lymphoma (DLBCL) and EBV+ classic Hodgkin lymphoma (CHL) are major B-cell lymphomas with EBV infection in elderly patients. Although they are regarded as distinct clinicopathological entities, distinguishing EBV+ CHL from EBV+ DLBCL is often challenging because of their overlapping histologic and immunophenotypic features. We characterized the spectrum of EBV+ large B-cell lymphoma (LBCL) in 57 patients aged 50 years or older, including 35 EBV+ DLBCL (12 polymorphic EBV+ DLBCL [pDLBCL] and 23 monomorphic EBV+ DLBCL [mDLBCL]) and 22 EBV+ CHL. Gene expression profiling revealed interferon gamma (IFN-γ) enrichment with overexpression of indoleamine 2,3-dioxygenase 1 (IDO1), an immunosuppressive enzyme, in more than half of pDLBCL (5/8) but less in mDLBCL (3/19) and CHL (1/19). Fluorescence in situ hybridization showed a higher frequency of 9p24.1-altered cells in CHL (54%; IQR, 42%-89%) but lower frequencies in pDLBCL (18%; IQR, 12%-23%) and mDLBCL (5%; IQR, 0%-30%). Notably, immunohistochemical expression of PDL1 was higher in pDLBCL than in mDLBCL, suggesting IFN-γ–mediated upregulation. DLBCL with EBV latency type III (n = 13) exhibited lower tumor PDL1 expression and reduced IDO1-enriched microenvironment. Multivariate analysis of the total cohort revealed that both EBV latency type III and Eastern Cooperative Oncology Group performance status ≥2 were independently associated with shorter overall survival. The EBV+ LBCL spectrum was reclassified into 4 molecular groups: (1) EBV latency type III suggestive of immune senescence (n = 10, 22%), (2) high proportion of 9p24.1 alteration (n = 9, 20%), (3) high IFN-γ signature score (n = 9, 20%), and (4) low IFN-γ signature score (n = 18, 39%). Moreover, these groups were identified using the following surrogate immunohistochemical markers: EBNA2, PDL1, and IDO1. In conclusion, the molecular studies assessing the tumor-host interaction enhance the understanding of the EBV+ LBCL spectrum and benefit pathological diagnosis and clinical management.
eb病毒阳性(EBV+)弥漫性大b细胞淋巴瘤(DLBCL)和EBV+经典霍奇金淋巴瘤(CHL)是老年eb病毒感染的主要b细胞淋巴瘤。尽管它们被认为是不同的临床病理实体,但由于其重叠的组织学和免疫表型特征,将EBV+ CHL与EBV+ DLBCL区分开来往往具有挑战性。我们分析了57例年龄≥50岁的EBV+大b细胞淋巴瘤,包括35例EBV+ DLBCL(12例多态DLBCL [pDLBCL], 23例单态DLBCL [mDLBCL])和22例EBV+ CHL。基因表达谱显示干扰素-γ (IFNγ)富集,免疫抑制酶吲哚胺2,3-双加氧酶1 (IDO1)在半数以上的pDLBCL(5/8)中过表达,而在mDLBCL(3/19)和CHL(1/19)中较少表达。荧光原位杂交显示,CHL中9p24.1改变的细胞频率较高(54%,四分位数范围[IQR], 42%-89%),而pDLBCL中9p24.1改变的细胞频率较低(18%,IQR, 12%-23%), mDLBCL中9p24.1改变的细胞频率较低(5%,IQR, 0%-30%)。值得注意的是,PDL1的免疫组化表达在pDLBCL中高于mDLBCL,提示ifn γ介导的上调。EBV潜伏期III型DLBCL (n = 13)表现出较低的肿瘤PDL1表达和较低的ido1富集微环境。总队列的多变量分析显示,EBV潜伏期III型和东部合作肿瘤组表现状态≥2与较短的总生存期独立相关。EBV+大b细胞淋巴瘤谱被重新划分为4个分子群:(1)EBV潜伏期III型提示免疫衰老(n = 10, 22%); (2) 9p24.1改变高比例(n = 9, 20%);(3) IFNγ高特征评分(n = 9, 20%)和(4)IFNγ低特征评分(n = 18, 39%)。此外,使用替代免疫组织化学标记:EBNA2、PDL1和IDO1来鉴定这些组。总之,评估肿瘤-宿主相互作用的分子研究增强了对EBV+大b细胞淋巴瘤谱的理解,有利于病理诊断和临床管理。
{"title":"Redefining the Spectrum of Epstein-Barr Virus–Positive (EBV+) Diffuse Large B-cell Lymphoma and EBV+ Classic Hodgkin Lymphoma","authors":"Shunsuke Nagase ,&nbsp;Naoya Nakamura ,&nbsp;Yara Yukie Kikuti ,&nbsp;Joaquim Carreras ,&nbsp;Yuki Tanigaki ,&nbsp;Makoto Orita ,&nbsp;Atsushi Ito ,&nbsp;Haruka Ikoma ,&nbsp;Hiroshi Kawada ,&nbsp;Yohei Masugi","doi":"10.1016/j.modpat.2025.100950","DOIUrl":"10.1016/j.modpat.2025.100950","url":null,"abstract":"<div><div>Epstein-Barr virus–positive (EBV+) diffuse large B-cell lymphoma (DLBCL) and EBV+ classic Hodgkin lymphoma (CHL) are major B-cell lymphomas with EBV infection in elderly patients. Although they are regarded as distinct clinicopathological entities, distinguishing EBV+ CHL from EBV+ DLBCL is often challenging because of their overlapping histologic and immunophenotypic features. We characterized the spectrum of EBV+ large B-cell lymphoma (LBCL) in 57 patients aged 50 years or older, including 35 EBV+ DLBCL (12 polymorphic EBV+ DLBCL [pDLBCL] and 23 monomorphic EBV+ DLBCL [mDLBCL]) and 22 EBV+ CHL. Gene expression profiling revealed interferon gamma (IFN-γ) enrichment with overexpression of indoleamine 2,3-dioxygenase 1 (IDO1), an immunosuppressive enzyme, in more than half of pDLBCL (5/8) but less in mDLBCL (3/19) and CHL (1/19). Fluorescence in situ hybridization showed a higher frequency of 9p24.1-altered cells in CHL (54%; IQR, 42%-89%) but lower frequencies in pDLBCL (18%; IQR, 12%-23%) and mDLBCL (5%; IQR, 0%-30%). Notably, immunohistochemical expression of PDL1 was higher in pDLBCL than in mDLBCL, suggesting IFN-γ–mediated upregulation. DLBCL with EBV latency type III (n = 13) exhibited lower tumor PDL1 expression and reduced IDO1-enriched microenvironment. Multivariate analysis of the total cohort revealed that both EBV latency type III and Eastern Cooperative Oncology Group performance status ≥2 were independently associated with shorter overall survival. The EBV+ LBCL spectrum was reclassified into 4 molecular groups: (1) EBV latency type III suggestive of immune senescence (n = 10, 22%), (2) high proportion of 9p24.1 alteration (n = 9, 20%), (3) high IFN-γ signature score (n = 9, 20%), and (4) low IFN-γ signature score (n = 18, 39%). Moreover, these groups were identified using the following surrogate immunohistochemical markers: EBNA2, PDL1, and IDO1. In conclusion, the molecular studies assessing the tumor-host interaction enhance the understanding of the EBV+ LBCL spectrum and benefit pathological diagnosis and clinical management.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100950"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of Ribosomal Protein L22 (RPL22) Expression Identifies a Transcriptional Subset of MLH1-Deficient Endometrial Cancers With Lower Numbers of Tumor-Associated Lymphocytes RPL22表达缺失鉴定了MLH1缺陷子宫内膜癌的转录亚群,其肿瘤相关淋巴细胞数量较低。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-09-24 DOI: 10.1016/j.modpat.2025.100899
Macy L. Osborne-Frazier , Savannah E. LaBuda , Molly L. Parrish , Hannah M. Atkins , Russell R. Broaddus , Andrew B. Gladden
Microsatellite instability-high defines one of the major subsets of endometrial cancer (EC), characterized by defects in DNA mismatch repair, most often by loss of MLH1 protein expression, and sensitivity to immunotherapies. RPL22 is selectively mutated in microsatellite instability-high cancers, resulting in loss of protein expression. The significance of this mutation is unknown. An immunohistochemistry assay was developed that reliably detected ECs with ribosomal protein L22 (RPL22) protein loss. With a cohort of ECs, we identified MLH1-deficient cancers with loss of RPL22 expression. Using digital spatial transcriptomics, a subset was identified that was characterized by no expression of RPL22, lower expression of β-2 microglobulin, lack of expression of immune activation pathways, and lower numbers of tumor-associated CD8+ lymphocytes. β-2 Microglobulin, which is necessary for antigen presentation to T lymphocytes, was decreased in EC cell lines with RPL22 knocked down. Neither RPL22 expression nor levels of tumor-associated T lymphocytes were associated with tumor mutation burden or PD-L1 expression, 2 biomarkers that are assessed in patients considered for immunotherapies. This study provides the first evidence that RPL22 deficiency is an easily measured indicator of a unique subset of MLH1-deficient ECs that can be characterized as immune low. Our study suggests that patients with RPL22-deficient tumors could represent poor candidates for CD8+ T-cell–based immunotherapies, a current frontline therapy for MLH1-deficient ECs.
msi -高定义了子宫内膜癌的主要亚群之一,其特征是DNA错配修复缺陷,最常见的是MLH1蛋白表达缺失,以及对免疫疗法的敏感性。RPL22在msi高的癌症中选择性突变,导致蛋白表达缺失。这种突变的意义尚不清楚。我们开发了一种免疫组织化学方法,可以可靠地检测RPL22蛋白缺失的子宫内膜癌。在一组子宫内膜癌中,我们发现了RPL22表达缺失的MLH1缺陷癌。利用数字空间转录组学,确定了一个亚群,其特征是RPL22不表达,β2M表达较低,免疫激活途径缺乏表达,肿瘤相关CD8+淋巴细胞数量较少。在RPL22缺失的子宫内膜癌细胞系中,抗原呈递到T淋巴细胞所必需的β2M减少。RPL22表达和肿瘤相关T淋巴细胞水平均与肿瘤突变负荷或PD-L1表达无关,这两种生物标志物在考虑接受免疫治疗的患者中被评估。这项工作提供了第一个证据,证明RPL22缺陷是MLH1缺陷子宫内膜癌的一个独特亚群的一个容易测量的指标,其特征是免疫低下。我们的研究表明,RPL22缺陷肿瘤患者可能不适合CD8+ T细胞免疫疗法,这是目前针对MLH1缺陷子宫内膜癌的一线治疗方法。
{"title":"Loss of Ribosomal Protein L22 (RPL22) Expression Identifies a Transcriptional Subset of MLH1-Deficient Endometrial Cancers With Lower Numbers of Tumor-Associated Lymphocytes","authors":"Macy L. Osborne-Frazier ,&nbsp;Savannah E. LaBuda ,&nbsp;Molly L. Parrish ,&nbsp;Hannah M. Atkins ,&nbsp;Russell R. Broaddus ,&nbsp;Andrew B. Gladden","doi":"10.1016/j.modpat.2025.100899","DOIUrl":"10.1016/j.modpat.2025.100899","url":null,"abstract":"<div><div>Microsatellite instability-high defines one of the major subsets of endometrial cancer (EC), characterized by defects in DNA mismatch repair, most often by loss of MLH1 protein expression, and sensitivity to immunotherapies. <em>RPL22</em> is selectively mutated in microsatellite instability-high cancers, resulting in loss of protein expression. The significance of this mutation is unknown. An immunohistochemistry assay was developed that reliably detected ECs with ribosomal protein L22 (RPL22) protein loss. With a cohort of ECs, we identified MLH1-deficient cancers with loss of RPL22 expression. Using digital spatial transcriptomics, a subset was identified that was characterized by no expression of RPL22, lower expression of β-2 microglobulin, lack of expression of immune activation pathways, and lower numbers of tumor-associated CD8+ lymphocytes. β-2 Microglobulin, which is necessary for antigen presentation to T lymphocytes, was decreased in EC cell lines with <em>RPL22</em> knocked down. Neither RPL22 expression nor levels of tumor-associated T lymphocytes were associated with tumor mutation burden or PD-L1 expression, 2 biomarkers that are assessed in patients considered for immunotherapies. This study provides the first evidence that RPL22 deficiency is an easily measured indicator of a unique subset of MLH1-deficient ECs that can be characterized as immune low. Our study suggests that patients with RPL22-deficient tumors could represent poor candidates for CD8+ T-cell–based immunotherapies, a current frontline therapy for MLH1-deficient ECs.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100899"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histological Categorization of Desmoplastic Reaction in Triple-Negative Breast Cancer: Its Relevance to Neoadjuvant Chemoimmunotherapy Response and Tumor Biology 三阴性乳腺癌结缔组织增生反应的组织学分类:与新辅助化疗免疫治疗反应和肿瘤生物学的相关性。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-26 DOI: 10.1016/j.modpat.2025.100943
Xunxi Lu , Bin Luo , Yani Wei , Hong Bu , Zongchao Gou
Neoadjuvant chemoimmunotherapy (NACi) is a new standard treatment for early-stage high-risk triple-negative breast cancer (TNBC). Desmoplastic reaction (DR) is an important characteristic in the tumor-associated stroma of TNBC. Based on the presence or absence of myxoid stroma and keloid-like collagen bundles within the tumor-associated stroma, DR was classified into immature, intermediate, or mature type. The relationship between DR and NACi efficacy remains unclear. We retrospectively analyzed 209 TNBC patients who received NACi from 3 medical centers, and 75, 78, and 56 cases were categorized as mature, intermediate, and immature types of DR, respectively. The pathological complete response rate was the highest in the mature group (77.3%), followed by the intermediate (30.8%) and immature (17.9%) groups. Multivariate logistic regression analysis indicated that in addition to histological type, Ki-67, T stage, N stage, and stromal tumor–infiltrating lymphocytes, DR was also an independent predictor of pathological complete response. Cases with intermediate and immature stroma exhibited fewer stromal tumor–infiltrating lymphocytes, an immunosuppressive tumor microenvironment, and upregulation of genes related to extracellular matrix and epithelial-mesenchymal transition. These findings demonstrate the predictive value of DR for NACi efficacy in TNBC and highlight its potential as a histopathological biomarker. The association between DR and molecular hallmarks provides important insights into the biological basis of DR in TNBC.
新辅助化疗免疫治疗(NACi)是早期高危三阴性乳腺癌(TNBC)的新标准治疗方法。结缔组织增生反应(DR)是TNBC肿瘤相关基质的一个重要特征。根据肿瘤相关基质中是否存在黏液样基质和瘢痕样胶原束,将DR分为未成熟型、中度型和成熟型。DR与NACi疗效之间的关系尚不清楚。我们回顾性分析了来自三个医疗中心的209例接受NACi治疗的TNBC患者,分别有75例、78例和56例被归类为成熟型、中度型和不成熟型DR。病理完全缓解(pCR)率以成熟组最高(77.3%),其次为中间组(30.8%)和未成熟组(17.9%)。多因素logistic回归分析表明,除了组织学类型、Ki-67、T分期、N分期和间质肿瘤浸润淋巴细胞(sTILs)外,DR也是pCR的独立预测因子。中间和未成熟间质的病例表现出较少的stil,免疫抑制的肿瘤微环境,以及与细胞外基质和上皮-间质转化相关的基因上调。这些发现证明了DR对TNBC中NACi疗效的预测价值,并强调了其作为组织病理学生物标志物的潜力。DR和分子标记之间的关联为TNBC中DR的生物学基础提供了重要的见解。
{"title":"Histological Categorization of Desmoplastic Reaction in Triple-Negative Breast Cancer: Its Relevance to Neoadjuvant Chemoimmunotherapy Response and Tumor Biology","authors":"Xunxi Lu ,&nbsp;Bin Luo ,&nbsp;Yani Wei ,&nbsp;Hong Bu ,&nbsp;Zongchao Gou","doi":"10.1016/j.modpat.2025.100943","DOIUrl":"10.1016/j.modpat.2025.100943","url":null,"abstract":"<div><div>Neoadjuvant chemoimmunotherapy (NACi) is a new standard treatment for early-stage high-risk triple-negative breast cancer (TNBC). Desmoplastic reaction (DR) is an important characteristic in the tumor-associated stroma of TNBC. Based on the presence or absence of myxoid stroma and keloid-like collagen bundles within the tumor-associated stroma, DR was classified into immature, intermediate, or mature type. The relationship between DR and NACi efficacy remains unclear. We retrospectively analyzed 209 TNBC patients who received NACi from 3 medical centers, and 75, 78, and 56 cases were categorized as mature, intermediate, and immature types of DR, respectively. The pathological complete response rate was the highest in the mature group (77.3%), followed by the intermediate (30.8%) and immature (17.9%) groups. Multivariate logistic regression analysis indicated that in addition to histological type, Ki-67, T stage, N stage, and stromal tumor–infiltrating lymphocytes, DR was also an independent predictor of pathological complete response. Cases with intermediate and immature stroma exhibited fewer stromal tumor–infiltrating lymphocytes, an immunosuppressive tumor microenvironment, and upregulation of genes related to extracellular matrix and epithelial-mesenchymal transition. These findings demonstrate the predictive value of DR for NACi efficacy in TNBC and highlight its potential as a histopathological biomarker. The association between DR and molecular hallmarks provides important insights into the biological basis of DR in TNBC.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100943"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mutational Signature in Cancers Following Solid Organ or Allogeneic Stem Cell Transplantation 实体器官或同种异体干细胞移植后癌症的新突变特征。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-10-22 DOI: 10.1016/j.modpat.2025.100921
Igor Odintsov , Stephanie E. Siegmund , Navin R. Mahadevan , Alanna J. Church , Lynette M. Sholl , Jonathan A. Nowak
Transplant recipients are at a heightened risk of cancer, yet the full spectrum of etiologic factors is poorly understood. In this study, we analysed the mutational patterns in a clinically diverse cohort of 41,874 cancers and identified a mutational signature highly associated with a history of solid organ or allogeneic stem cell transplantation. This signature is characterized by a high tumor mutation burden and a striking predominance of C>A single base substitutions, particularly in the 5′-C[C>A]A-3′ trinucleotide context. We identified 13 transplant recipients whose tumors harbored this signature, which is distinct from previously described mutational processes, including those related to tobacco, defective DNA repair, or polymerase mutations. The discovery of this signature points to a mutagenic force in this vulnerable patient group and provides new insights into the pathogenesis of transplant-associated malignancies.
移植受者患癌症的风险较高,但其全部病因尚不清楚。在这里,我们分析了临床多样化的41874例癌症的突变模式,并确定了一个与实体器官或同种异体干细胞移植史高度相关的新的突变特征。该特征的特点是高肿瘤突变负担和C bbbba单碱基取代的显著优势,特别是在5‘-C[C> a] a -3’三核苷酸背景下。我们确定了13名移植受者,他们的肿瘤中含有这种特征,这与先前描述的突变过程不同,包括与烟草、DNA修复缺陷或聚合酶突变相关的突变过程。这一特征的发现指出了这一脆弱患者群体中以前未被认识到的诱变力,并为移植相关恶性肿瘤的发病机制提供了新的见解。
{"title":"Mutational Signature in Cancers Following Solid Organ or Allogeneic Stem Cell Transplantation","authors":"Igor Odintsov ,&nbsp;Stephanie E. Siegmund ,&nbsp;Navin R. Mahadevan ,&nbsp;Alanna J. Church ,&nbsp;Lynette M. Sholl ,&nbsp;Jonathan A. Nowak","doi":"10.1016/j.modpat.2025.100921","DOIUrl":"10.1016/j.modpat.2025.100921","url":null,"abstract":"<div><div>Transplant recipients are at a heightened risk of cancer, yet the full spectrum of etiologic factors is poorly understood. In this study, we analysed the mutational patterns in a clinically diverse cohort of 41,874 cancers and identified a mutational signature highly associated with a history of solid organ or allogeneic stem cell transplantation. This signature is characterized by a high tumor mutation burden and a striking predominance of C&gt;A single base substitutions, particularly in the 5′-C[C&gt;A]A-3′ trinucleotide context. We identified 13 transplant recipients whose tumors harbored this signature, which is distinct from previously described mutational processes, including those related to tobacco, defective DNA repair, or polymerase mutations. The discovery of this signature points to a mutagenic force in this vulnerable patient group and provides new insights into the pathogenesis of transplant-associated malignancies.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100921"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145368301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories 乳腺癌HER2报告的国际专家共识建议:关注HER2低和超低类别。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-10-28 DOI: 10.1016/j.modpat.2025.100925
Emad A. Rakha , Puay Hoon Tan , Mieke R. Van Bockstal , Kimberly H. Allison , Edi Brogi , Grace Callagy , Gábor Cserni , Shabnam Jaffer , Maria Pia Foschini , Helenice Gobbi , Janina Kulka , Xiaoxian Li , Elena Provenzano , Abeer M. Shaaban , Gary M. Tse , Zsuzsanna Varga , Anne Vincent-Salomon , Rin Yamaguchi , Wentao Yang , Soha ElSheikh , Cecily Quinn
The concept of “HER2-negative” breast cancer is evolving, with the recognition of HER2-low and HER2-ultralow subsets. These subsets are clinically relevant regarding treatment with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which has shown survival benefit in patients with metastatic carcinoma with minimal HER2 protein expression that lack HER2 gene amplification by in situ hybridization. In clinical trials using T-DXd, HER2-low was defined as an immunohistochemistry (IHC) score 1+ or an IHC score 2+ without HER2 gene amplification. HER2-ultralow was defined as faint or barely perceptible, incomplete membrane staining in >0% to ≤10% of tumor cells (IHC score 0+/with membrane staining) and HER2-null as the complete absence of staining (IHC score 0/absent membrane staining). These results now necessitate more detailed evaluation and reporting of traditional “HER2-negative” results to identify patients with metastatic breast cancer who may benefit from T-DXd therapy. Both the US Food and Drug Administration and the European Medicines Agency have extended the regulatory approval of T-DXd to patients with metastatic breast cancer showing HER2-low or HER2-ultralow expressions. Updated clinical management guidelines now, therefore, incorporate the spectrum of HER2 results into treatment selection algorithms in the metastatic setting. To align histopathologic practice with these developments, the College of American Pathologists has issued a new biomarker-reporting template that recommends explicit distinction between IHC 0/absent membrane staining and IHC 0+/with membrane staining. Key concerns among pathologists include assay variability, scoring reproducibility, and quality assurance standards for accurately detecting such low levels of HER2 expression. This manuscript provides expert consensus, evidence-based practical recommendations for identifying and reporting tumors with HER2-low and HER2-ultralow expression. We emphasize standardized testing protocols, validated assays, robust internal and external controls, and focused training for pathologists. A universal structured pathology report is proposed to highlight the accurate distinction between IHC 0 (null), IHC 0+ (ultralow), and HER2-low expressions.
随着her2低亚群和her2超低亚群的认识,“her2阴性”乳腺癌的概念也在不断发展。这些亚群与抗体-药物偶联曲妥珠单抗德鲁西替康(T-DXd)的治疗具有临床相关性,该药物已显示出HER2蛋白表达极低且缺乏HER2基因原位杂交(ISH)扩增的转移性癌患者的生存益处。在使用T-DXd的临床试验中,HER2-low被定义为免疫组织化学(IHC)评分1+或IHC评分2+,没有HER2基因扩增。her2 -超低定义为肿瘤细胞中有0 ~ 10%的肿瘤细胞出现微弱或几乎无法察觉的不完全膜染色(IHC评分0+/伴有膜染色),her2 -零定义为完全无染色(IHC评分0/伴有膜染色)。这些结果现在需要对传统的“her2阴性”结果进行更详细的评估和报告,以确定可能从T-DXd治疗中受益的转移性乳腺癌患者。美国食品和药物管理局(FDA)和欧洲药品管理局(EMA)已将T-DXd的监管批准延长至her2低或her2超低表达的转移性乳腺癌患者。因此,现在更新的临床管理指南将HER2结果谱纳入转移性肿瘤的治疗选择算法中。为了使组织病理学实践与这些发展保持一致,美国病理学家学会(CAP)发布了一个新的生物标志物报告模板,建议明确区分IHC 0/无膜染色和IHC 0+/有膜染色。病理学家主要关注的问题包括测定的可变性、评分的可重复性和准确检测如此低水平HER2表达的质量保证标准。该手稿提供了专家共识,基于证据的实用建议,用于识别和报告her2低和her2超低表达的肿瘤。我们强调标准化的检测方案,有效的分析,强大的内部和外部控制,以及对病理学家的重点培训。提出一份通用的结构化病理报告,以强调IHC 0(零)、IHC 0+(超低)和her2低表达之间的准确区分。
{"title":"International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories","authors":"Emad A. Rakha ,&nbsp;Puay Hoon Tan ,&nbsp;Mieke R. Van Bockstal ,&nbsp;Kimberly H. Allison ,&nbsp;Edi Brogi ,&nbsp;Grace Callagy ,&nbsp;Gábor Cserni ,&nbsp;Shabnam Jaffer ,&nbsp;Maria Pia Foschini ,&nbsp;Helenice Gobbi ,&nbsp;Janina Kulka ,&nbsp;Xiaoxian Li ,&nbsp;Elena Provenzano ,&nbsp;Abeer M. Shaaban ,&nbsp;Gary M. Tse ,&nbsp;Zsuzsanna Varga ,&nbsp;Anne Vincent-Salomon ,&nbsp;Rin Yamaguchi ,&nbsp;Wentao Yang ,&nbsp;Soha ElSheikh ,&nbsp;Cecily Quinn","doi":"10.1016/j.modpat.2025.100925","DOIUrl":"10.1016/j.modpat.2025.100925","url":null,"abstract":"<div><div>The concept of “HER2-negative” breast cancer is evolving, with the recognition of HER2-low and HER2-ultralow subsets. These subsets are clinically relevant regarding treatment with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which has shown survival benefit in patients with metastatic carcinoma with minimal HER2 protein expression that lack <em>HER2</em> gene amplification by in situ hybridization. In clinical trials using T-DXd, HER2-low was defined as an immunohistochemistry (IHC) score 1+ or an IHC score 2+ without <em>HER2</em> gene amplification. HER2-ultralow was defined as faint or barely perceptible, incomplete membrane staining in &gt;0% to ≤10% of tumor cells (IHC score 0+/with membrane staining) and HER2-null as the complete absence of staining (IHC score 0/absent membrane staining). These results now necessitate more detailed evaluation and reporting of traditional “HER2-negative” results to identify patients with metastatic breast cancer who may benefit from T-DXd therapy. Both the US Food and Drug Administration and the European Medicines Agency have extended the regulatory approval of T-DXd to patients with metastatic breast cancer showing HER2-low or HER2-ultralow expressions. Updated clinical management guidelines now, therefore, incorporate the spectrum of HER2 results into treatment selection algorithms in the metastatic setting. To align histopathologic practice with these developments, the College of American Pathologists has issued a new biomarker-reporting template that recommends explicit distinction between IHC 0/absent membrane staining and IHC 0+/with membrane staining. Key concerns among pathologists include assay variability, scoring reproducibility, and quality assurance standards for accurately detecting such low levels of HER2 expression. This manuscript provides expert consensus, evidence-based practical recommendations for identifying and reporting tumors with HER2-low and HER2-ultralow expression. We emphasize standardized testing protocols, validated assays, robust internal and external controls, and focused training for pathologists. A universal structured pathology report is proposed to highlight the accurate distinction between IHC 0 (null), IHC 0+ (ultralow), and HER2-low expressions.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100925"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Discordance and Error in Breast Pathology: Causes, Classifications, and Medicolegal Implications 乳腺病理诊断的不一致和错误:原因、分类和医学法律意义。
IF 5.5 1区 医学 Q1 PATHOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-22 DOI: 10.1016/j.modpat.2025.100942
Emad A. Rakha , Cecily M. Quinn , Elena Provenzano , Sarah E. Pinder , Ian O. Ellis
Diagnostic pathology is inherently interpretative and subject to interobserver variability. Although diagnostic concordance is a critical quality metric, distinguishing between acceptable variation, diagnostic error, and professional negligence is essential for both clinical care and medicolegal clarity. This review highlights the difference between interobserver variability (diagnostic disagreement/discordance) that remains within acceptable professional limits, diagnostic error (a deviation from expected standards due to cognitive, technical, or systemic factors), and negligence (a repeated, reckless, or unjustified deviation from established standards). Errors in pathology often reflect systemic vulnerabilities, such as workflow inefficiencies, inadequate quality control, or limited biopsy sampling, rather than individual performance alone. They may occur at any stage of the diagnostic pathway (preanalytical, analytical, or postanalytical) and arise from specimen misidentification, contamination or loss, inadequate sampling, or incomplete documentation. Pathologist-related errors encompass failure to recognize significant pathology, misinterpretation, omission of appropriate ancillary studies, insufficient workup of complex cases, including failure to seek a second opinion, or substandard reporting. Medicolegal implications are heightened when such errors result in delayed diagnosis or major misclassification, leading to patient harm. In breast pathology, interobserver variation in the classification of borderline lesions (eg, grading of phyllodes tumors) and in the interpretation of overlapping entities (eg, atypical apocrine lesions) is well recognized. Although such differences may influence management, they should be regarded as acceptable professional variability, rather than error or negligence. To minimize diagnostic risk and uphold standards, structured reporting, vigilance in complex cases, participation in quality assurance, explicit documentation of uncertainty, active multidisciplinary team engagement, and laboratory accreditation are strongly recommended. Supporting pathologists as diagnosticians and patient safety advocates, within a culture of openness, shared learning, and institutional support, remains central to diagnostic accuracy, transparency, and medicolegal defensibility.
诊断病理学本质上是解释性的,并受制于观察者之间的差异。虽然诊断一致性是一个关键的质量指标,区分可接受的变异、诊断错误和专业疏忽对于临床护理和医学法律清晰度都是至关重要的。本综述强调了在可接受的专业范围内的观察者间可变性(诊断分歧/不一致)、诊断错误(由于认知、技术或系统因素而偏离预期标准)和疏忽(重复、鲁莽或不合理地偏离既定标准)之间的区别。病理错误通常反映的是系统脆弱性,如工作流程效率低下、质量控制不足或活检样本有限,而不仅仅是个人表现。它们可能发生在诊断途径的任何阶段(分析前、分析后或分析后),由标本错误鉴定、污染或丢失、取样不充分或文件不完整引起。病理学相关的错误包括未能认识到重要的病理,误解,遗漏适当的辅助研究,对复杂病例的检查不足,包括未能寻求第二意见,或报告不合格。当此类错误导致延误诊断或严重错误分类,从而导致患者受到伤害时,医学法律影响就会加剧。在乳腺病理学中,在边缘病变的分类(如分叶状肿瘤的分级)和重叠实体(如非典型大汗腺病变)的解释中,观察者之间的差异是公认的。虽然这些差异可能影响管理,但它们应被视为可接受的专业变异性,而不是错误或疏忽。为了最大限度地降低诊断风险和维护标准,强烈建议进行结构化报告、对复杂病例保持警惕、参与质量保证、明确记录不确定性、积极的多学科团队参与和实验室认证。在开放、共享学习和机构支持的文化中,支持病理学家作为诊断医生和患者安全倡导者,仍然是诊断准确性、透明度和医学法律可辩护性的核心。
{"title":"Diagnostic Discordance and Error in Breast Pathology: Causes, Classifications, and Medicolegal Implications","authors":"Emad A. Rakha ,&nbsp;Cecily M. Quinn ,&nbsp;Elena Provenzano ,&nbsp;Sarah E. Pinder ,&nbsp;Ian O. Ellis","doi":"10.1016/j.modpat.2025.100942","DOIUrl":"10.1016/j.modpat.2025.100942","url":null,"abstract":"<div><div>Diagnostic pathology is inherently interpretative and subject to interobserver variability. Although diagnostic concordance is a critical quality metric, distinguishing between acceptable variation, diagnostic error, and professional negligence is essential for both clinical care and medicolegal clarity. This review highlights the difference between interobserver variability (diagnostic disagreement/discordance) that remains within acceptable professional limits, diagnostic error (a deviation from expected standards due to cognitive, technical, or systemic factors), and negligence (a repeated, reckless, or unjustified deviation from established standards). Errors in pathology often reflect systemic vulnerabilities, such as workflow inefficiencies, inadequate quality control, or limited biopsy sampling, rather than individual performance alone. They may occur at any stage of the diagnostic pathway (preanalytical, analytical, or postanalytical) and arise from specimen misidentification, contamination or loss, inadequate sampling, or incomplete documentation. Pathologist-related errors encompass failure to recognize significant pathology, misinterpretation, omission of appropriate ancillary studies, insufficient workup of complex cases, including failure to seek a second opinion, or substandard reporting. Medicolegal implications are heightened when such errors result in delayed diagnosis or major misclassification, leading to patient harm. In breast pathology, interobserver variation in the classification of borderline lesions (eg, grading of phyllodes tumors) and in the interpretation of overlapping entities (eg, atypical apocrine lesions) is well recognized. Although such differences may influence management, they should be regarded as acceptable professional variability, rather than error or negligence. To minimize diagnostic risk and uphold standards, structured reporting, vigilance in complex cases, participation in quality assurance, explicit documentation of uncertainty, active multidisciplinary team engagement, and laboratory accreditation are strongly recommended. Supporting pathologists as diagnosticians and patient safety advocates, within a culture of openness, shared learning, and institutional support, remains central to diagnostic accuracy, transparency, and medicolegal defensibility.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"39 1","pages":"Article 100942"},"PeriodicalIF":5.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Modern Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1